An immunological comparison between lipidated and non-lipidated multivalent HIV-1 peptides representing Gp120 and Gag hypervariable regions

Vaccine

Volumn 29, Issue 35, 2011, Pages 5950-5958

  Ghunaim, Haitham ^a,b   Kumar, Ashok ^a,b   Torres, Jose ^c   Diaz Mitoma, Francisco ^a   Azizi, Ali ^a,b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Gag; Gp120; HIV; Peptides; Vaccine

Indexed keywords

GAG PROTEIN; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS 1 PEPTIDE VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PEPTIDE VACCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN ANTIBODY REACTION; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

AIDS VACCINES; AMINO ACID SEQUENCE; ANIMALS; GENE PRODUCTS, GAG; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HLA-A2 ANTIGEN; HUMANS; IMMUNE SERA; LIPOPEPTIDES; MICE; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; PEPTIDES; T-LYMPHOCYTES;

EID: 79960738803     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.06.047     Document Type: Article

References (48)

1. Azizi A., Kumar A., Diaz-Mitoma F., Mestecky J. Enhancing oral vaccine potency by targeting intestinal M cells. PLoS Pathog 2010, 6(11):e1001147.
2. Sirskyj D., Diaz-Mitoma F., Golshani A., Kumar A., Azizi A. Innovative bioinformatic approaches for developing peptide-based vaccines against hypervariable viruses. Immunol Cell Biol 2011, 89(January (1)):81-89.
3. Azizi A., Anderson D.E., Torres J.V., Ogrel A., Ghorbani M., Soare C., et al. Induction of broad cross-subtype-specific HIV-1 immune responses by a novel multivalent HIV-1 peptide vaccine in cynomolgus macaques. J Immunol 2008, 180(February (4)):2174-2186.
4. Carlos M.P., Anderson D.E., Gardner M.B., Torres J.V. Immunogenicity of a vaccine preparation representing the variable regions of the HIV type 1 envelope glycoprotein. AIDS Res Hum Retroviruses 2000, 16(January (2)):153-161.
5. Ahlers J.D., Belyakov I.M. Lessons learned from natural infection: focusing on the design of protective T cell vaccines for HIV/AIDS. Trends Immunol 2010, 31(March (3)):120-130.
6. Appay V., Zaunders J.J., Papagno L., Sutton J., Jaramillo A., Waters A., et al. Characterization of CD4(+) CTLs ex vivo. J Immunol 2002, 168(June (11)):5954-5958.
7. Tarosso L.F., Sauer M.M., Sanabani S., Giret M.T., Tomiyama H.I., Sidney J., et al. Unexpected diversity of cellular immune responses against Nef and Vif in HIV-1-infected patients who spontaneously control viral replication. PLoS One 2010, 5(7):e11436.
8. van Leeuwen E.M., Sprent J., Surh C.D. Generation and maintenance of memory CD4(+) T Cells. Curr Opin Immunol 2009, 21(April (2)):167-172.
9. Wan Y.Y. Multi-tasking of helper T cells. Immunology 2010, 130(June (2)):166-171.
10. Saenz S.A., Noti M., Artis D. Innate immune cell populations function as initiators and effectors in Th2 cytokine responses. Trends Immunol 2010, 31(November (11)):407-413.
11. Wang C., Sanders C.M., Yang Q., Schroeder H.W., Wang E., Babrzadeh F., et al. High throughput sequencing reveals a complex pattern of dynamic interrelationships among human T cell subsets. Proc Natl Acad Sci U S A 2010, 107(January (4)):1518-1523.
12. Phillips R.E., Rowland-Jones S., Nixon D.F., Gotch F.M., Edwards J.P., Ogunlesi A.O., et al. Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature 1991, 354(December (6353)):453-459.
13. Price D.A., Goulder P.J., Klenerman P., Sewell A.K., Easterbrook P.J., Troop M., et al. Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection. Proc Natl Acad Sci U S A 1997, 94(March (5)):1890-1895.
14. Barouch D.H. Challenges in the development of an HIV-1 vaccine. Nature 2008, 455(October (7213)):613-619.
15. Korber B.T., Letvin N.L., Haynes B.F. T-cell vaccine strategies for human immunodeficiency virus, the virus with a thousand faces. J Virol 2009, 83(September (17)):8300-8314.
16. Celum C., Wald A., Hughes J., Sanchez J., Reid S., Delany-Moretlwe S., et al. Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. Lancet 2008, 371(June (9630)):2109-2119.
17. Rowland-Jones S.L., Dong T., Fowke K.R., Kimani J., Krausa P., Newell H., et al. Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi. J Clin Invest 1998, 102(November (9)):1758-1765.
18. Monceaux V., Viollet L., Petit F., Ho Tsong Fang R., Cumont M.C., Zaunders J., et al. CD8+ T cell dynamics during primary simian immunodeficiency virus infection in macaques: relationship of effector cell differentiation with the extent of viral replication. J Immunol 2005, 174(June (11)):6898-6908.
19. Jin X., Gao X., Ramanathan M., Deschenes G.R., Nelson G.W., O'Brien S.J., et al. Human immunodeficiency virus type 1 (HIV-1)-specific CD8+-T-cell responses for groups of HIV-1-infected individuals with different HLA-B*35 genotypes. J Virol 2002, 76(December (24)):12603-12610.
20. Rerks-Ngarm S., Pitisuttithum P., Nitayaphan S., Kaewkungwal J., Chiu J., Paris R., et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009, 361(December (23)):2209-2220.
21. Azizi A., Ghunaim H., Diaz-Mitoma F., Mestecky J., Mucosal HIV vaccines: a holy grail or a dud?. Vaccine 2010, 28(May (24)):4015-4026.
22. Belyakov I.M., Ahlers J.D. Functional CD8+ CTLs in mucosal sites and HIV infection: moving forward toward a mucosal AIDS vaccine. Trends Immunol 2008, 29(November (11)):574-585.
23. Gowen B.B., Wong M.H., Jung K.H., Sanders A.B., Mitchell W.M., Alexopoulou L., et al. TLR3 is essential for the induction of protective immunity against Punta Toro Virus infection by the double-stranded RNA (dsRNA), poly(I:C12U), but not Poly(I:C): differential recognition of synthetic dsRNA molecules. J Immunol 2007, 178(April (8)):5200-5208.
24. Wulff S., Pries R., Wollenberg B. Cytokine release of human NK cells solely triggered with Poly I:C. Cell Immunol 2010, 263(2):135-137.
25. Duluc D., Tan F., Scotet M., Blanchard S., Fremaux I., Garo E., et al. PolyI:C plus IL-2 or IL-12 induce IFN-gamma production by human NK cells via autocrine IFN-beta. Eur J Immunol 2009, 39(October (10)):2877-2884.
26. Goonetilleke N., Liu M.K., Salazar-Gonzalez J.F., Ferrari G., Giorgi E., Ganusov V.V., et al. The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J Exp Med 2009, 206(June (6)):1253-1272.
27. McMichael A.J., Borrow P., Tomaras G.D., Goonetilleke N., Haynes B.F. The immune response during acute HIV-1 infection: clues for vaccine development. Nat Rev Immunol 2010, 10(January (1)):11-23.
28. Liu Y., McNevin J., Rolland M., Zhao H., Deng W., Maenza J., et al. Conserved HIV-1 epitopes continuously elicit subdominant cytotoxic T-lymphocyte responses. J Infect Dis 2009, 200(December (12)):1825-1833.
29. Barouch D.H. Novel adenovirus vector-based vaccines for HIV-1. Curr Opin HIV AIDS 2010, 5(September (5)):386-390.
30. Jaoko W., Karita E., Kayitenkore K., Omosa-Manyonyi G., Allen S., Than S., et al. Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa. PLoS One 2010, 5(9):e12873.
31. Saez-Cirion A., Lacabaratz C., Lambotte O., Versmisse P., Urrutia A., Boufassa F., et al. HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. Proc Natl Acad Sci U S A 2007, 104(April (16)):6776-6781.
32. Kiepiela P., Ngumbela K., Thobakgale C., Ramduth D., Honeyborne I., Moodley E., et al. CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med 2007, 13(January (1)):46-53.
33. Liu J., O'Brien K.L., Lynch D.M., Simmons N.L., La Porte A., Riggs A.M., et al. Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature 2009, 457(January (7225)):87-91.
34. Li H., Chen X., Jin X., Liu Z., Huang X., Cao Z., et al. Proliferation, but not interleukin 2 production, of Gag-specific CD8+ T cells is associated with low HIV viremia and high CD4 counts in HIV-1-infected Chinese individuals. J Acquir Immune Defic Syndr 2009, 52(September (1)):1-8.
35. Sachdeva N., Weinstein J.E., Ashman M., Sachdeva M., Brewer T.H., Gracia D., et al. Poor lymphoproliferative responses with low proportion of Gag-specific CD8 TEMRA cells in HIV-1-infected patients showing immunological and virological discordance despite prolonged suppression of plasma viremia. Viral Immunol 2010, 23(February (1)):49-61.
36. Wanjalla C.N., Faul E.J., Gomme E.A., Schnell M.J. Dendritic cells infected by recombinant rabies virus vaccine vector expressing HIV-1 Gag are immunogenic even in the presence of vector-specific immunity. Vaccine 2010, (August).
37. Jackson D.C., Lau Y.F., Le T., Suhrbier A., Deliyannis G., Cheers C., et al. A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses. Proc Natl Acad Sci U S A 2004, 101(October (43)):15440-15445.
38. Pialoux G., Gahery-Segard H., Sermet S., Poncelet H., Fournier S., Gerard L., et al. Lipopeptides induce cell-mediated anti-HIV immune responses in seronegative volunteers. AIDS 2001, 15(July (10)):1239-1249.
39. BenMohamed L., Krishnan R., Auge C., Primus J.F., Diamond D.J. Intranasal administration of a synthetic lipopeptide without adjuvant induces systemic immune responses. Immunology 2002, 106(May (1)):113-121.
40. BenMohamed L., Belkaid Y., Loing E., Brahimi K., Gras-Masse H., Druilhe P. Systemic immune responses induced by mucosal administration of lipopeptides without adjuvant. Eur J Immunol 2002, 32(August (8)):2274-2281.
41. Eriksson E.M., Jackson D.C. Recent advances with TLR2-targeting lipopeptide-based vaccines. Curr Protein Pept Sci 2007, 8(August (4)):412-417.
42. Borsutzky S., Fiorelli V., Ebensen T., Tripiciano A., Rharbaoui F., Scoglio A., et al. Efficient mucosal delivery of the HIV-1 Tat protein using the synthetic lipopeptide MALP-2 as adjuvant. Eur J Immunol 2003, 33(June (6)):1548-1556.
43. Chentoufi A.A., Dasgupta G., Christensen N.D., Hu J., Choudhury Z.S., Azeem A., et al. A novel HLA (HLA-A*0201) transgenic rabbit model for preclinical evaluation of human CD8+ T cell epitope-based vaccines against ocular herpes. J Immunol 2010, 184(March (5)):2561-2571.
44. Chentoufi A.A., Benmohamed L. Future viral vectors for the delivery of asymptomatic herpes epitope-based immunotherapeutic vaccines. Future Virol 2010, 5(September (5)):525-528.
45. Dasgupta G., Nesburn A.B., Wechsler S.L., BenMohamed L. Developing an asymptomatic mucosal herpes vaccine: the present and the future. Future Microbiol 2010, 5(January (1)):1-4.
46. Betts M.R., Nason M.C., West S.M., De Rosa S.C., Migueles S.A., Abraham J., et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 2006, 107(June (12)):4781-4789.
47. Migueles S.A., Osborne C.M., Royce C., Compton A.A., Joshi R.P., Weeks K.A., et al. Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control. Immunity 2008, 29(December (6)):1009-1021.
48. Reynolds M.R., Rakasz E., Skinner P.J., White C., Abel K., Ma Z.M., et al. CD8+ T-lymphocyte response to major immunodominant epitopes after vaginal exposure to simian immunodeficiency virus: too late and too little. J Virol 2005, 79(July (14)):9228-9235.